Open Label, Prospective, Exploratory Study to Investigate the Effect of Inhaled CHF5993 pMDI on Central and Peripheral Airway Dimensions in COPD Patients by Functional Respiratory Imaging
Phase of Trial: Phase III
Latest Information Update: 22 Feb 2019
At a glance
- Drugs Beclometasone/formoterol/glycopyrrolate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Acronyms FRI
- Sponsors Chiesi Farmaceutici SpA
- 18 Feb 2019 Status changed from recruiting to completed.
- 27 Nov 2018 Planned End Date changed from 30 Sep 2018 to 30 Jun 2019.
- 27 Nov 2018 Planned primary completion date changed from 30 Sep 2018 to 30 Jan 2019.